Publications by authors named "Qianyu Jing"
Article Synopsis
- Lung cancer is a major cause of cancer deaths, and a new treatment method called immunotherapy is showing promise, especially for a type called non-small cell lung cancer (NSCLC).
- Research suggests that combining different treatments, like PD-1 inhibitors, PTP1B inhibitors, and TNFR2 antibodies (called triple therapy), can work better together to fight this cancer.
- In studies with mice, this triple therapy reduced tumor size and helped the mice live longer by improving the activity and amount of certain immune cells that attack the cancer.
Purpose: This study aimed to develop a novel and feasible modification strategy to improve the solubility and antitumor activity of resiquimod (R848) by utilizing the supramolecular effect of 2-hydroxypropyl-beta-cyclodextrin (2-HP-β-CD).
Methods: R848-loaded PLGA nanoparticles modified with 2-HP-β-CD (CD@R848@NPs) were synthesized using an enhanced emulsification solvent-evaporation technique. The nanoparticles were then characterized in vitro by several methods, such as scanning electron microscopy (SEM), differential scanning calorimetry (DSC), Fourier transform infrared (FTIR) spectroscopy, particle size analysis, and zeta potential analysis.
Immunotherapy is regarded as a potent cancer treatment, with DC vaccines playing a crucial role. Although clinical trials have demonstrated the safety and efficacy of DC vaccines, loading antigens in vitro is challenging, and their therapeutic effects remain unpredictable. Moreover, the diverse subtypes and maturity states of DCs in the body could induce both immune responses and immune tolerance, potentially affecting the vaccine's efficacy.
View Article and Find Full Text PDFAs psychoneuroimmunology flourishes, there is compelling evidence that depression suppresses the anti-tumor immune response, promotes the progression of cancer, and inhibits the effectiveness of cancer immunotherapy. Recent studies have reported that antidepressants can not only alleviate the depressant condition of cancer patients, but also strengthen the anti-tumor immunity, thus suppressing tumors. Tumor necrosis factor receptor 2 (TNFR2) antagonistic antibodies (Anti-TNFR2) targeting tumor-infiltrating regulatory T cells (Tregs) has achieved great results in preclinical studies, and with a favorable toxicity profile than existing immunotherapies, and is expected to become a new generation of more effective treatment strategies.
View Article and Find Full Text PDFLung cancer has the highest incidence rate and mortality worldwide. Moreover, multiple factors may cause heterogeneity in the efficacy of immunotherapy for lung cancer, and preclinical studies have gradually uncovered the promotive effects of psychological distress (PD) on tumor hallmarks. Therefore, treatment targeted at PD may be a vital factor in adjusting and improving immunotherapy for lung cancer.
View Article and Find Full Text PDFArticle Synopsis
- Immunotherapy, particularly dendritic cell (DC) vaccine therapy, is an emerging cancer treatment method, although traditional DC vaccination struggles with precise targeting and requires optimization.
- The presence of immunosuppressive CD4Foxp3 regulatory T cells (Tregs) in tumors can hinder immune response, leading to a focus on strategies that target Tregs for better immunotherapy outcomes.
- In this study, the combination of HMGN1 (a TLR4 agonist) and 3M-052 (a TLR7/8 agonist) was shown to enhance DC maturation and proinflammatory cytokine production, showing promise in a colon cancer mouse model by reducing tumor growth through the activation of cytotoxic CD8 T